宠物用贝那普利的研究进展
|
摘要
随着宠物高血压、心脏病等疾病的发病率逐年上升,抗高血压、心脏病药物的研究在不断的探索与实践中得到发展。然而,我国宠物高血压、心脏疾病的控制率、治疗率却有待提高。本文将近些年来国内外血管紧张素转化酶抑制剂(ACEI)中贝那普利的理化性质、合成方法、药理学、药代学研究及临床应用进行了概述,并对用药所产生的不良反应情况作了安全的分析与评价,从而进一步指导兽医临床用药,以期贝那普利在宠物临床中更安全、更有效地使用。
With the incidence of hypertension and heart disease in pets increasing year by year,research of anti-cardiopathic and hypertension drugs has gained achievements in long clinical practice. However,the effects of control and treatment of these pet diseases have yet to be improved urgently. This article reviews worldwide researches in recent years on the physicochemical property,synthesis process,pharmacology pharmacokinetics and clinical application in pets of benazepril in angiotensin converting enzyme inhibitors( ACEI) and evaluates the safety and drug adverse reactions,in the hope of guiding veterinary clinical administration of benazepril in a more effective and safe manner.
With the incidence of hypertension and heart disease in pets increasing year by year,research of anti-cardiopathic and hypertension drugs has gained achievements in long clinical practice. However,the effects of control and treatment of these pet diseases have yet to be improved urgently. This article reviews worldwide researches in recent years on the physicochemical property,synthesis process,pharmacology pharmacokinetics and clinical application in pets of benazepril in angiotensin converting enzyme inhibitors( ACEI) and evaluates the safety and drug adverse reactions,in the hope of guiding veterinary clinical administration of benazepril in a more effective and safe manner.
引文
[1] Sioufi A,Pommier F,Kaiser G,et al. Determination of benazepril,a new angiotensin-converting enzyme inhibitor,and its active metabolite,benazeprilat,in plasma and urine by capillary gas chromatography-mass-selective detection[J]. J Chromatogr A,1988,434(1):239-246.
[2] King J N,Maurer M,Toutain P L. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats[J]. J Vet Pharmacol Ther,2003,26(3):213-224.
[3] Toutain P L,Lefebvre H P,Laroute V. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors:case of enalapril and benazepril in dogs[J]. J Pharmacol Exp Ther,2000,292(3):1094-1103.
[4] Urbach H,Henning R. A favourable diastereoselective synthesis of N-(1-S-ethoxycarbonyl-3-phenylpropyl)-S-alanine[J]. Tetrahedron Lett,1984,25(11):1143-1146.
[5] Kumar T R,Yatendra K. Process for the preparation of benazepril:WO,02076375[P]. 2002-10-03.
[6] Boyer S K,Pfund R A,Portmann R E,et al. Notiz zur synthese eines optisch aktiven ace-hemmers mit amino-oxo-benzazepin-1-alkansure-struktur mittels enantiokonvergierender kristallisationsinduzierter racemat trennung[J]. Helv Chim Acta,1988,71(2):337-343.
[7]奚春明,庞奇超.盐酸贝那普利产业化工艺研究[J].上海医药,2017,38(17):72-74.
[8]刘丽,王旭慧,袁易.国产盐酸贝那普利的降压疗效及不良反应研究[J].中南药学,2017,15(5):691-693.
[9]孙西征,林文清,陈代勇,等;抗高血压药物盐酸贝那普利的研究进展[J].西南国防医药,2003,13(2):216-218.
[10] Atkins C,Bonagura J,Ettinger S,et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease[J]. J Vet Intern Med,2009,23(6):1142-1150.
[11] Mochel J P,Peyrou M,Fink M,et al. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System(RAAS)peptides heightens the understanding of the effect of benazepril in dogs[J]. J Vet Pharmacol Ther,2013,36(2):174-180.
[12]宋蓉.盐酸贝那普利及其主要代谢物在健康中国人中的研究[D].北京:中国协和医科大学,2007.
[13] King J N,Maurer M,Morrison C A,et al. Pharmacokinetics of the angiotensin-convertingenzyme inhibitor,benazepril,and its active metabolite,benazeprilat,in dog[J]. Xenobiotica,1997,27(8):819-829.
[14]王志敏.盐酸贝那普利对犬的安全性试验及犬充血性心力衰竭的疗效研究[D].南京:南京农业大学,2013.
[15] Mizutani H,Koyama H,Watanabe T,et al. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats[J]. J Vet Intern Med,2006,20(5):1074-1079.
[16] King J N,Gunn-Moore D A,Tasker S,et al. Tolerability and efficacy of benazepril in cats with chronic kidney disease[J]. J Vet Intern Med,2006,20(5):1054-1064.
[17] Pouchelon J L,King J,Martignoni L,et al. Long-term tolerability of benazepril in dogs with congestive heart failure[J]. J Vet Cardiol,2004,6(1):7-13.
[18] Pouchelon J L,Jamet N,Gouni V,et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease:A retrospective study of 141 cases[J]. J Vet Intern Med,2008,22(4):905-914.
[19] Mishina M,Watanabe T. Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure[J]. J Vet Med Sci,2008,70(5):455-460.
[20]单化瑞,单平,许春晓.贝那普利治疗原发性高血压[J].中国社区医师(医学专业半月刊),2009(16):34.
[21] O'Grady M R,O'Sullivan M L,Minors S L,et al. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers[J]. J Vet Intern Med,2009,23:977-983.
[22]梁冰,刘章锁,程根阳,等.贝那普利联合氯沙坦对环孢素A致大鼠慢性肾毒性的防治作用[J].郑州大学学报(医学版),2007(6):1055-1057.
[23]孟宇,金海峰,郑海兰,等.来氟米特联合贝那普利对糖尿病肾病大鼠肾组织TGF-β1和CTGF表达的影响[J].中国老年学杂志,2014,34(10):2778-2781.
[24]魏春燕.曲美他嗪和贝那普利联用对异丙肾致大鼠心肌损伤的影响[D]南昌:南昌大学,2010.
[25]郝丽娜,侯少科,李建辉,等.贝那普利与丙泊酚联合对糖尿病模型大鼠心肌缺血再灌注的影响[J].中国老年学杂志,2015,35(20):5744-5747.
[26]余雄杰,刘生友. 36例贝那普利致不良反应文献分析[J].中国药房,2007,18(14):1104-1105.
[27]汪斌.贝那普利治疗慢性心力衰竭的疗效观察30例[J].中国医药指南,2010,8(23):59-60.
[28] Chetboul V,Lefebvre H P,Sampedrano C C,et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease:a prospective,controlled,blinded,and randomized study[J]. J Vet Intern Med,2007,21(4):742-753.
[29]王晓波.盐酸贝那普利乐卡地平片毒代动力学研究[D].济南:山东大学,2015.
[30] Pouchelon J L,King J,Martignoni L,et al. Long-term tolerability of benazepril in dogs with congestive heart failure[J]. J Vet Cardiol,2004,6(1):7-13.
[2] King J N,Maurer M,Toutain P L. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats[J]. J Vet Pharmacol Ther,2003,26(3):213-224.
[3] Toutain P L,Lefebvre H P,Laroute V. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors:case of enalapril and benazepril in dogs[J]. J Pharmacol Exp Ther,2000,292(3):1094-1103.
[4] Urbach H,Henning R. A favourable diastereoselective synthesis of N-(1-S-ethoxycarbonyl-3-phenylpropyl)-S-alanine[J]. Tetrahedron Lett,1984,25(11):1143-1146.
[5] Kumar T R,Yatendra K. Process for the preparation of benazepril:WO,02076375[P]. 2002-10-03.
[6] Boyer S K,Pfund R A,Portmann R E,et al. Notiz zur synthese eines optisch aktiven ace-hemmers mit amino-oxo-benzazepin-1-alkansure-struktur mittels enantiokonvergierender kristallisationsinduzierter racemat trennung[J]. Helv Chim Acta,1988,71(2):337-343.
[7]奚春明,庞奇超.盐酸贝那普利产业化工艺研究[J].上海医药,2017,38(17):72-74.
[8]刘丽,王旭慧,袁易.国产盐酸贝那普利的降压疗效及不良反应研究[J].中南药学,2017,15(5):691-693.
[9]孙西征,林文清,陈代勇,等;抗高血压药物盐酸贝那普利的研究进展[J].西南国防医药,2003,13(2):216-218.
[10] Atkins C,Bonagura J,Ettinger S,et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease[J]. J Vet Intern Med,2009,23(6):1142-1150.
[11] Mochel J P,Peyrou M,Fink M,et al. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System(RAAS)peptides heightens the understanding of the effect of benazepril in dogs[J]. J Vet Pharmacol Ther,2013,36(2):174-180.
[12]宋蓉.盐酸贝那普利及其主要代谢物在健康中国人中的研究[D].北京:中国协和医科大学,2007.
[13] King J N,Maurer M,Morrison C A,et al. Pharmacokinetics of the angiotensin-convertingenzyme inhibitor,benazepril,and its active metabolite,benazeprilat,in dog[J]. Xenobiotica,1997,27(8):819-829.
[14]王志敏.盐酸贝那普利对犬的安全性试验及犬充血性心力衰竭的疗效研究[D].南京:南京农业大学,2013.
[15] Mizutani H,Koyama H,Watanabe T,et al. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats[J]. J Vet Intern Med,2006,20(5):1074-1079.
[16] King J N,Gunn-Moore D A,Tasker S,et al. Tolerability and efficacy of benazepril in cats with chronic kidney disease[J]. J Vet Intern Med,2006,20(5):1054-1064.
[17] Pouchelon J L,King J,Martignoni L,et al. Long-term tolerability of benazepril in dogs with congestive heart failure[J]. J Vet Cardiol,2004,6(1):7-13.
[18] Pouchelon J L,Jamet N,Gouni V,et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease:A retrospective study of 141 cases[J]. J Vet Intern Med,2008,22(4):905-914.
[19] Mishina M,Watanabe T. Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure[J]. J Vet Med Sci,2008,70(5):455-460.
[20]单化瑞,单平,许春晓.贝那普利治疗原发性高血压[J].中国社区医师(医学专业半月刊),2009(16):34.
[21] O'Grady M R,O'Sullivan M L,Minors S L,et al. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers[J]. J Vet Intern Med,2009,23:977-983.
[22]梁冰,刘章锁,程根阳,等.贝那普利联合氯沙坦对环孢素A致大鼠慢性肾毒性的防治作用[J].郑州大学学报(医学版),2007(6):1055-1057.
[23]孟宇,金海峰,郑海兰,等.来氟米特联合贝那普利对糖尿病肾病大鼠肾组织TGF-β1和CTGF表达的影响[J].中国老年学杂志,2014,34(10):2778-2781.
[24]魏春燕.曲美他嗪和贝那普利联用对异丙肾致大鼠心肌损伤的影响[D]南昌:南昌大学,2010.
[25]郝丽娜,侯少科,李建辉,等.贝那普利与丙泊酚联合对糖尿病模型大鼠心肌缺血再灌注的影响[J].中国老年学杂志,2015,35(20):5744-5747.
[26]余雄杰,刘生友. 36例贝那普利致不良反应文献分析[J].中国药房,2007,18(14):1104-1105.
[27]汪斌.贝那普利治疗慢性心力衰竭的疗效观察30例[J].中国医药指南,2010,8(23):59-60.
[28] Chetboul V,Lefebvre H P,Sampedrano C C,et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease:a prospective,controlled,blinded,and randomized study[J]. J Vet Intern Med,2007,21(4):742-753.
[29]王晓波.盐酸贝那普利乐卡地平片毒代动力学研究[D].济南:山东大学,2015.
[30] Pouchelon J L,King J,Martignoni L,et al. Long-term tolerability of benazepril in dogs with congestive heart failure[J]. J Vet Cardiol,2004,6(1):7-13.